KREBSBIO

Krebs Biochemicals & Industries Share Price

₹97.36 -1.69 (-1.71%)

22 Dec, 2024 22:04

SIP TrendupStart SIP in KREBSBIO

Start SIP

Performance

  • Low
  • ₹97
  • High
  • ₹102
  • 52 Week Low
  • ₹60
  • 52 Week High
  • ₹129
  • Open Price₹100
  • Previous Close₹99
  • Volume3,850

Investment Returns

  • Over 1 Month + 18.34%
  • Over 3 Month + 9.68%
  • Over 6 Month + 36.51%
  • Over 1 Year + 25.14%
SIP Lightning

Smart Investing Starts Here Start SIP with Krebs Biochemicals & Industries for Steady Growth!

Invest Now

Krebs Biochemicals & Industries Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -9.6
  • PEG Ratio
  • 5.8
  • Market Cap Cr
  • 210
  • P/B Ratio
  • -1.8
  • Average True Range
  • 6.68
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • 4.13
  • RSI
  • 46.34
  • MFI
  • 53.92

Krebs Biochemicals & Industries Financials

Krebs Biochemicals & Industries Technicals

EMA & SMA

Current Price
₹97.36
-1.69 (-1.71%)
pointer
  • stock-down_img
  • Bullish Moving Average 7
  • stock-up_img
  • Bearish Moving Average 9
  • 20 Day
  • ₹102.20
  • 50 Day
  • ₹96.17
  • 100 Day
  • ₹90.43
  • 200 Day
  • ₹85.08

Resistance and Support

98.79 Pivot Speed
  • R3 105.57
  • R2 103.79
  • R1 100.57
  • S1 95.57
  • S2 93.79
  • S3 90.57

What's your outlook on Krebs Biochemicals & Industries?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Krebs Biocs.& Inds. has an operating revenue of Rs. 50.69 Cr. on a trailing 12-month basis. An annual revenue de-growth of -4% needs improvement, Pre-tax margin of -39% needs improvement, ROE of 0% is poor and needs improvement. NULL The stock from a technical standpoint is comfortably placed above its key moving averages, around 7% and 22% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -18% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 14 which is a POOR score indicating inconsistency in earnings, a RS Rating of 66 which is FAIR indicating the recent price performance, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 53 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Krebs Biochemicals & Industries Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-11 Quarterly Results & Other To Consider Other business matters.
2024-08-07 Quarterly Results
2024-05-21 Audited Results
2024-02-12 Quarterly Results
2023-11-08 Quarterly Results

Krebs Biochemicals & Industries F&O

Krebs Biochemicals & Industries Shareholding Pattern

72.74%
0.5%
19.8%
6.96%

About Krebs Biochemicals & Industries

  • NSE Symbol
  • KREBSBIO
  • BSE Symbol
  • 524518
  • Managing Director & CEO
  • Mr. Jitendra Shah
  • ISIN
  • INE268B01013

Similar Stocks to Krebs Biochemicals & Industries

Krebs Biochemicals & Industries FAQs

Krebs Biochemicals & Industries share price is ₹97 As on 22 December, 2024 | 21:50

The Market Cap of Krebs Biochemicals & Industries is ₹209.9 Cr As on 22 December, 2024 | 21:50

The P/E ratio of Krebs Biochemicals & Industries is -9.6 As on 22 December, 2024 | 21:50

The PB ratio of Krebs Biochemicals & Industries is -1.8 As on 22 December, 2024 | 21:50

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23